Literature DB >> 15004327

Soluble amyloid beta-protein is increased in frontotemporal dementia with tau gene mutations.

Antonella Vitali1, Alessandra Piccini, Roberta Borghi, Pantaleo Fornaro, Sandra L Siedlak, Mark A Smith, Pierluigi Gambetti, Bernardino Ghetti, Massimo Tabaton.   

Abstract

The relationship between senile plaques and neurofibrillary tangles, the main pathologic lesions of Alzheimer's disease, is not completely understood. We addressed this issue examining the type and amount of amyloid beta-protein (Abeta) associated with the soluble and insoluble tissue fractions in the frontal cortex of 8 cases with frontotemporal dementia with parkinsonism caused by mutations of the Tau gene (FTDP-17), in which the intracellular accumulation of polymerised tau is definitely the primary cause of neurodegeneration. As control, we examined 7 cases with frontotemporal dementia lacking distinctive histopathology (DLDH) as well as 8 pathologically normal subjects. In all cases the presence of Abeta deposits was ruled out using immunocytochemistry on sections adjacent to those used for biochemical analysis. ELISA analysis showed a 2.7 and 2.1 fold (p < 0.01) increase of soluble Abeta42 and Abeta40 in FTDP-17, compared to normal and DLDH brains, both of which had comparable levels of Abeta species. Furthermore, the immunoreactivity of the intracellular Abeta42 was significantly increased in cortical neurons of subjects affected with FTDP-17. The results demonstrate that the aggregation of tau protein produces an accumulation of Abeta, which, however, does not reach the critical concentration needed for Abetaplaques formation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15004327     DOI: 10.3233/jad-2004-6106

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  3 in total

1.  Decreased cerebrospinal fluid amyloid beta (1-40) levels in frontotemporal lobar degeneration.

Authors:  Y A L Pijnenburg; S N M Schoonenboom; P D Mehta; S P Mehta; C Mulder; R Veerhuis; M A Blankenstein; P Scheltens
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-03-19       Impact factor: 10.154

2.  CSF biomarkers in frontotemporal lobar degeneration: relations with clinical characteristics, apolipoprotein E genotype, and neuroimaging.

Authors:  Y A L Pijnenburg; S N M Schoonenboom; F Barkhof; D L Knol; C Mulder; G J Van Kamp; J C Van Swieten; P Scheltens
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-02       Impact factor: 10.154

3.  Slowly progressive dementia caused by MAPT R406W mutations: longitudinal report on a new kindred and systematic review.

Authors:  Emil Ygland; Danielle van Westen; Elisabet Englund; Rosa Rademakers; Zbigniew K Wszolek; Karin Nilsson; Christer Nilsson; Maria Landqvist Waldö; Irina Alafuzoff; Oskar Hansson; Lars Gustafson; Andreas Puschmann
Journal:  Alzheimers Res Ther       Date:  2018-01-09       Impact factor: 6.982

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.